Results 221 to 230 of about 997,958 (247)

Left ventricular diastolic dysfunction worsens prognosis in patients with heart failure due to dilated cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1183-1193, April 2025.
Abstract Aims The prognostic significance of left ventricular (LV) diastolic dysfunction (LVDD) severity in patients with dilated cardiomyopathy (DCM) remains uncertain. This study aimed to evaluate the association of LVDD severity and elevated left atrial pressure (eLAP) with patient outcomes in stable, non‐acutely decompensated patients with DCM ...
Mateusz Winiarczyk, Ewa Dziewięcka, Sylwia Wiśniowska‐Śmiałek, Agnieszka Stępień, Katarzyna Graczyk, Agata Leśniak‐Sobelga, Marta Hlawaty, Jakub Woźniak, Maryia Savitskaya, Katarzyna Holcman, Magdalena Kostkiewicz, Piotr Podolec, Paweł Rubiś   +12 more
wiley   +1 more source

Recent advances in research on the multifactorial mechanisms underlying paclitaxel resistance and translational intervention strategies. [PDF]

Front Pharmacol
Mingjun Z, Bingwen Z, Lu W, Zhimin F.
europepmc   +1 more source

Lupeol as a modulator of bacterial resistance mediated by the MepA efflux pump in Staphylococcus aureus. [PDF]

Naunyn Schmiedebergs Arch Pharmacol
Araújo NJS, Silva CAP, Oliveira-Tintino CDM, Alencar GG, do Socorro Costa M, da Silva ARP, Soares JB, Rocha JE, Tintino SR, Lima-Bezerra V, Coutinho HDM, Rodrigues VLC, Barbosa-Filho JM, de Araújo-Neto JB, Araujo ACF, de Oliveira Borges JA, de Araújo GA, da Costa Silva JT, Andrade-Pinheiro JC.   +18 more
europepmc   +1 more source

Evaluation of Novel Benzo-Annelated 1,4-Dihydropyridines as Potential Inhibitors of Antibacterial Efflux Pumps in <i>S. aureus</i> and MRSA Strains. [PDF]

Int J Mol Sci
Werner P, Szemerédi N, Spengler G, Erdmann F, Hilgeroth A.   +4 more
europepmc   +1 more source

Effect of polymyxin resistance evolution on the fitness costs of Acinetobacter baumannii and the underlying mechanisms of polymyxin resistance. [PDF]

Sci Rep
Wang Q, Sun F, Huang T, Yuan Q, Shen Z, Feng W.   +5 more
europepmc   +1 more source

A Clinical Case of Treatment-Emergent Acinetobacter baumannii Non-Susceptibility to Sulbactam-Durlobactam. [PDF]

Clin Infect Dis
Sharara SL, Diaz L, Asempa TE, Martinez JRW, Canales N, Bergman Y, Murphy SG, Karaba SM, Clark AE, Zurawski DV, Cosgrove SE, Simner PJ, Munita JM, Tamma PD.   +13 more
europepmc   +1 more source

MexXY-OprM efflux pump mediates resistance to odilorhabdins in <i>Pseudomonas aeruginosa</i>. [PDF]

Microbiol Spectr
Racine E, Pantel L, Maurent K, Fuchs HLS, Sarciaux M, Houard J, Hinkelmann B, Attwood M, Muller C, Guénard S, Noel A, MacGowan A, Givaudan A, Brönstrup M, Gualtieri M.   +14 more
europepmc   +1 more source

Farnesol, a Potential Efflux Pump Inhibitor in Mycobacterium smegmatis

Molecules, 2010
The active multidrug efflux pump (EP) has been described as one of the mechanisms involved in the natural drug resistance of bacteria, such as mycobacteria. As a result, the development of efflux pumps inhibitors (EPIs) is an important topic.
Jing Jin, Ji-Yu Zhang, Ming-Yuan Liu
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Role of Berberine as a Potential Efflux Pump Inhibitor against MdfA from Escherichia coli: In Vitro and In Silico Studies.

Microbiology Spectrum, 2023
Xizhen Ge
exaly